Clinical trial
Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00003533 · Burzynski Research Institute, Other · Terminated
Key facts
| NCT number | NCT00003533 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer |
| Official title | Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Prostate Cancer |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 12 |
| Start date | Feb 27, 1996 |
| Primary completion | Dec 31, 1999 |
| Completion | Dec 31, 1999 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: